Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
ConditionTraumatic Brain Injury
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTang-Du Hospital
About this trial
The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.
Eligibility criteria
Qualifiers
Age 18 years older and younger than 80 years old.
Definite history of traumatic brain injury.
Admission within≤24 hours after the traumatic brain injury.
CT scans demonstrate intracerebral hemorrhage/contusions with and without extracerebral hemorrhage (epi- and sub- dural hemorrhage)
Disqualifiers
Time of head injury cannot be reliably assessed.
Subjects is considered a candidate for immediate surgical intervention because of severe extracranial injury.
Open head injury.
Pregnancy or parturition within previous 30 days or active lactation.
Trial design
Treatments tested in this trial
- Baricitinib 4 MG
- Standard treatment
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Tang-Du Hospital
Lead sponsor
Qianxian People's Hospital
Collaborator
Weinan Central Hospital
Collaborator
Second Affiliated Hospital of Xi'an Jiaotong University
Collaborator
The First Hospital of Yulin
Collaborator
Xidian Group Hospital
Collaborator
Chongqing University Central Hospital & Chongqing Emergency Medical Center
Collaborator
The Peoples' Hospital of Jiaozuo City
Collaborator
First People's Hospital of Xianyang
Collaborator
987th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Collaborator
Chongqing Hospital of PAP
Collaborator
Baoji Fengxiang District Hospital
Collaborator
GEM Flower Xian Changqing Staff Hospital
Collaborator
Source ClinicalTrials.gov